Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load

The study, which has now been completed, is an independent, investigator-initiated, randomised, double-blind placebo study led by Professor Glen Davison, Head of School of Sport and Exercise Sciences at the University of Kent in England.

The secondary endpoints have now been reported as significant. All the results are official on the trial registry site: https://doi.org/10.1186/ISRCTN18133939.

The study involved 164 endurance athletes who used either ColdZyme or placebo when experiencing upper respiratory tract infection symptoms. The difference between ColdZyme and placebo proved significant.

"The primary endpoint showed that the duration of URT infection was significantly reduced, meaning the athletes in the ColdZyme group recovered from the infection and could return to full training much sooner. The secondary endpoints showed a significantly lower viral load for Rhinovirus (the most common cause of a cold), with ColdZyme vs placebo treatment, lower symptom rating scores, and fewer training days lost for the athletes in the study. For example, athletes were typically losing 3-4 days of training in the placebo group compared to 1-2 days in the ColdZyme group”, said Professor Glen Davison.

“These results indicate that ColdZyme addresses the underlying cause of the URT infections, inhibiting the viruses’ ability to infect cells further, stopping the spread of the virus between cells and allowing the body to eliminate and ‘get over’ the virus infection more quickly. As a result, the responses and associated symptoms are less severe”, Professor Glen Davison continued.

“The results from this study on athletes can be translated into the broader society, namely the reduction in workdays lost to infection-caused illness, with less suffering, leading to added healthcare advantages that the wider population can benefit from in everyday life”, said Claus Egstrand, CEO of Enzymatica

The study will be submitted for peer review.

Secondary endpoints reported:

• Symptom relief (Total Jackson Score):     Significant vs. placebo
• Number of lost training days:                    Significant vs. placebo
• Viral load reduction:                                    Significant vs. placebo   

Facts

ColdZyme® is a mouth spray that protects against upper respiratory tract viruses causing common cold and flu-like symptoms. ColdZyme® is easy to use and acts fast. ColdZyme® forms a protective moisturizing barrier on the mucous membrane of the oral cavity and throat. The barrier disables viruses and inhibits their ability to spread and multiply.
 

ColdZyme has been certified according to the EU regulation MDR (class III) by the notified body Eurofins. The certification entails stricter requirements for the evidence of clinical validity, safe design and market surveillance. ColdZyme® products are now MDR certified with the following expanded intended use:

Read more at www.ColdZyme.se

The information in the press release is such that Enzymatica is obliged to make public according to the EU's market abuse regulation. The information was submitted, through the contact person below, for publication on 5 September 2024, at 20:30 CET.